Two GHRH analogues and one GHRP — compared across receptor targets, half-lives, GH pulse patterns, stacking synergy, and research applications.
The key insight that makes this comparison unique is that CJC-1295 and sermorelin operate through the GHRH receptor, while ipamorelin operates through the GHS-R1a (ghrelin receptor). These are entirely separate receptor systems with complementary mechanisms — which is why combining one GHRH analogue with ipamorelin produces synergistic GH release that exceeds either compound alone.
CJC-1295 and sermorelin bind the pituitary GHRH receptor, activating adenylyl cyclase via Gs protein coupling. This increases intracellular cAMP, which activates PKA and drives GH gene transcription and vesicular release. CJC-1295's DAC modification extends this receptor occupancy from minutes (sermorelin) to days.
Ipamorelin binds GHS-R1a, a Gq-coupled receptor that activates phospholipase C, increasing intracellular IP3 and DAG. This triggers calcium release from the ER and activates PKC — a completely separate signaling cascade from the GHRH pathway. The dual-pathway stimulation when combined with a GHRH analogue produces supra-additive GH release.
Among all GHRPs (GHRP-2, GHRP-6, hexarelin, ipamorelin), ipamorelin is uniquely selective for GH release without co-stimulating ACTH/cortisol or prolactin. GHRP-2 and GHRP-6 produce meaningful cortisol spikes that can counteract the anabolic benefits of GH elevation. Ipamorelin's selectivity makes it the only GHRP suitable for long-term stacking with GHRH analogues in research protocols.
| Parameter | CJC-1295 | Sermorelin | Ipamorelin |
|---|---|---|---|
| Compound Class | GHRH analogue (DAC-modified) | GHRH analogue (truncated) | GHRP / GHS-R1a agonist |
| Receptor Target | GHRH receptor (pituitary) | GHRH receptor (pituitary) | GHS-R1a (ghrelin receptor) |
| Amino Acid Length | 29 aa + DAC modification | 29 aa (GHRH 1–29) | 5 aa (pentapeptide) |
| Plasma Half-Life | ~6–8 days | ~10–12 minutes | ~2 hours |
| GH Release Pattern | Sustained (non-pulsatile) | Pulsatile (physiological) | Acute pulse (2–3 hr window) |
| Dosing Frequency | 1–2× per week | Daily (bedtime preferred) | 1–3× daily |
| Cortisol Elevation | Minimal | Minimal | None (highly selective) |
| Appetite Stimulation | None | None | Minimal (vs GHRP-6) |
| IGF-1 Elevation | Sustained (days) | Mild to moderate | Moderate (acute) |
| Synergy with Each Other | Excellent with ipamorelin | Good with ipamorelin | Excellent with CJC-1295 |
| Sleep Quality Evidence | Moderate | Good (bedtime protocol) | Good (pre-sleep dosing) |
| Muscle Anabolism Evidence | Moderate (+ ipamorelin stack) | Limited | Moderate (via IGF-1) |
| Fat Loss Evidence | Moderate | Limited | Moderate (via GH/IGF-1) |
| FDA Status | Research compound | Research compound | Research compound |
CJC-1295: 1–2 mg SC, 1–2× per week. Ipamorelin: 100–300 mcg SC, 1–3× daily (pre-sleep + pre-workout). Cycle: 12–16 weeks on, 4–8 weeks off.
CJC-1295's sustained GHRH receptor occupancy maintains elevated baseline GH/IGF-1, while ipamorelin's GHS-R1a stimulation produces acute GH pulses through a complementary pathway. The combination produces synergistic GH release exceeding either compound alone.
Sermorelin: 200–500 mcg SC, nightly at bedtime. Ipamorelin: 100–200 mcg SC, co-administered at bedtime. Cycle: 3–6 months continuous, then reassess.
Both compounds have short half-lives that produce a single large nocturnal GH pulse when co-dosed at bedtime — closely mimicking the natural GH secretion pattern of younger adults. This pulsatile pattern is preferred for sleep architecture research and anti-aging protocols.
Ipamorelin: 200–300 mcg SC, 2–3× daily (pre-sleep, pre-workout, morning). Cycle: 8–12 weeks on, 4 weeks off.
Ipamorelin alone is used when GHRH receptor stimulation is contraindicated or when a simpler protocol is preferred. Its selectivity (no cortisol, no prolactin, minimal appetite stimulation) makes it the safest standalone GHRP for introductory GH secretagogue research.
| Research Goal | Recommended Protocol | Rationale |
|---|---|---|
| Muscle anabolism / body recomposition | CJC-1295 + Ipamorelin | Sustained IGF-1 elevation + synergistic dual-pathway GH stimulation |
| Anti-aging / GH restoration | Sermorelin + Ipamorelin | Physiological pulsatile GH pattern closest to youthful secretion |
| Sleep quality improvement | Sermorelin + Ipamorelin (bedtime) | Amplifies natural nocturnal GH pulse during slow-wave sleep |
| Convenience / weekly dosing | CJC-1295 + Ipamorelin | CJC-1295 requires only 1–2 injections per week |
| Cortisol-sensitive protocol | Ipamorelin monotherapy | No ACTH/cortisol elevation at any dose; safest standalone GHRP |
| Introductory GH secretagogue | Sermorelin or Ipamorelin mono | Short half-lives allow rapid washout if adverse effects occur |
| Fat loss (visceral adiposity) | CJC-1295 + Ipamorelin | Sustained GH/IGF-1 elevation drives lipolysis more effectively than pulsatile patterns |
Source Research-Grade Peptides
CJC-1295, Sermorelin & Ipamorelin at Purgo Labs
≥99% purity · 3rd-party COA verified · Ships same day
CJC-1295 and sermorelin are both GHRH analogues — they bind the GHRH receptor on pituitary somatotrophs to stimulate GH secretion. Ipamorelin is a GHRP (growth hormone releasing peptide) and ghrelin mimetic — it binds the GHS-R1a receptor through an entirely different pathway. CJC-1295 has a 6–8 day half-life (with DAC modification), sermorelin has a ~10–12 minute half-life, and ipamorelin has a ~2 hour half-life. Because CJC-1295/sermorelin and ipamorelin act on different receptors, combining them produces synergistic GH release that exceeds either compound alone.
Both combinations are used in research, but CJC-1295 + ipamorelin is more widely studied and produces more sustained GH/IGF-1 elevation due to CJC-1295's 6–8 day half-life. Sermorelin + ipamorelin is preferred when physiological pulsatility is the priority — the short half-lives of both compounds produce a more natural GH pulse pattern. For body recomposition and muscle anabolism research, CJC-1295 + ipamorelin is the more commonly referenced protocol. For anti-aging and sleep quality research, sermorelin + ipamorelin is often preferred.
Combining CJC-1295 and sermorelin simultaneously is not recommended because they compete for the same GHRH receptor and provide no additive benefit. The correct approach is to choose one GHRH analogue (CJC-1295 or sermorelin) and combine it with ipamorelin. Adding a second GHRH analogue to the stack does not increase GH output and increases cost and injection burden without benefit.
Ipamorelin is uniquely selective among GHRPs — it does not significantly elevate cortisol or prolactin at research doses, unlike GHRP-2 and GHRP-6. This selectivity is ipamorelin's primary clinical advantage over other GHRPs and is why it is the preferred GHRP partner for CJC-1295 and sermorelin stacks. GHRP-2 and GHRP-6 produce meaningful cortisol spikes that can counteract the anabolic benefits of GH elevation.
The most commonly referenced research protocol for CJC-1295 + ipamorelin is: CJC-1295 (with DAC) at 1–2 mg subcutaneously 1–2 times per week, combined with ipamorelin at 100–300 mcg subcutaneously 1–3 times daily (typically pre-sleep and/or pre-workout). The combination exploits CJC-1295's sustained GHRH receptor occupancy and ipamorelin's acute GHS-R1a stimulation to produce synergistic GH pulses. All dosing information is for research purposes only.
Ipamorelin, GHRP-2, and GHRP-6 are all GHS-R1a agonists (ghrelin mimetics), but differ in selectivity. Ipamorelin is the most selective — it stimulates GH release without significantly elevating cortisol, prolactin, or appetite. GHRP-6 strongly stimulates appetite (via ghrelin pathways) and causes moderate cortisol elevation. GHRP-2 produces the strongest GH pulse of the three but also the highest cortisol spike. For research protocols where cortisol elevation is undesirable, ipamorelin is the preferred GHRP.
All three compounds can improve sleep quality through GH-mediated mechanisms, but sermorelin has the most research specifically on sleep architecture. GH is primarily secreted during slow-wave sleep, and sermorelin's bedtime dosing protocol is designed to amplify this natural nocturnal GH pulse. Ipamorelin also enhances slow-wave sleep GH secretion when dosed pre-sleep. CJC-1295's continuous GH elevation may be less optimal for sleep quality due to its non-pulsatile pattern.
Both compounds address GH decline associated with aging (somatopause), but through different mechanisms. Sermorelin more closely mimics the physiological GHRH pattern of younger adults, making it the preferred choice for researchers focused on restoring youthful GH pulsatility. CJC-1295 produces higher sustained IGF-1 levels, which may be more relevant for researchers focused on tissue repair and body composition. Most anti-aging research protocols combine one GHRH analogue with ipamorelin for synergistic effects.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.